The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity

Michael W. Graner, Angela Romanoski, Emmanuel Katsanis

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Tumour-derived chaperone-rich cell lysate (CRCL) when isolated from tumour tissue or when embedded with peptide antigens is a potent anti-cancer vaccine consisting of numerous chaperone/heat shock proteins, including the highly immunogenic Hsp70, Hsp90, glucose regulated protein 94, and calreticulin. We have previously documented that CRCL provides both a source of tumour antigens and danger signals triggering antigen presenting cell activation. In this report we describe the 'peptidome' of potential antigens extracted from CRCL prepared from a murine tumour. Using mass spectrometry techniques we identify almost 60 different proteins of origin for the CRCL peptides; we determine that the parental proteins come from essentially all parts of the cell, and are involved in a broad range of functions. Further in silico analysis demonstrates that the parental proteins are components of major signalling networks of vital importance for cancer cell survival, proliferation, and migration. In many instances the peptides identified possess amino acid sequences that would allow their putative binding and display by murine major histocompatibility complex class I and II molecules, and there are also predicted binding motifs for Hsp70-type chaperones. By mixing fractionated pools of peptides with antigen-free (normal liver) CRCL, we were able to reconstitute effective anti-tumour activity of the vaccine, showing that the peptides are indeed the major purveyors of CRCL vaccines' efficacy.

Original languageEnglish (US)
Pages (from-to)380-389
Number of pages10
JournalInternational Journal of Hyperthermia
Volume29
Issue number5
DOIs
StatePublished - Aug 2013

Fingerprint

Cancer Vaccines
Neoplasm Antigens
Immunity
Peptides
Neoplasms
Antigens
Calreticulin
Proteins
Antigen-Presenting Cells
Heat-Shock Proteins
Major Histocompatibility Complex
Computer Simulation
Cell Movement
Amino Acid Sequence
Mass Spectrometry
Cell Survival
Vaccines
Cell Proliferation
Liver

Keywords

  • Cancer vaccine
  • Heat shock proteins
  • Peptide antigens
  • Tumour immunity

ASJC Scopus subject areas

  • Cancer Research
  • Physiology
  • Radiological and Ultrasound Technology
  • Physiology (medical)

Cite this

The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. / Graner, Michael W.; Romanoski, Angela; Katsanis, Emmanuel.

In: International Journal of Hyperthermia, Vol. 29, No. 5, 08.2013, p. 380-389.

Research output: Contribution to journalArticle

@article{85d5c2ca28304602a5df64785f2029af,
title = "The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity",
abstract = "Tumour-derived chaperone-rich cell lysate (CRCL) when isolated from tumour tissue or when embedded with peptide antigens is a potent anti-cancer vaccine consisting of numerous chaperone/heat shock proteins, including the highly immunogenic Hsp70, Hsp90, glucose regulated protein 94, and calreticulin. We have previously documented that CRCL provides both a source of tumour antigens and danger signals triggering antigen presenting cell activation. In this report we describe the 'peptidome' of potential antigens extracted from CRCL prepared from a murine tumour. Using mass spectrometry techniques we identify almost 60 different proteins of origin for the CRCL peptides; we determine that the parental proteins come from essentially all parts of the cell, and are involved in a broad range of functions. Further in silico analysis demonstrates that the parental proteins are components of major signalling networks of vital importance for cancer cell survival, proliferation, and migration. In many instances the peptides identified possess amino acid sequences that would allow their putative binding and display by murine major histocompatibility complex class I and II molecules, and there are also predicted binding motifs for Hsp70-type chaperones. By mixing fractionated pools of peptides with antigen-free (normal liver) CRCL, we were able to reconstitute effective anti-tumour activity of the vaccine, showing that the peptides are indeed the major purveyors of CRCL vaccines' efficacy.",
keywords = "Cancer vaccine, Heat shock proteins, Peptide antigens, Tumour immunity",
author = "Graner, {Michael W.} and Angela Romanoski and Emmanuel Katsanis",
year = "2013",
month = "8",
doi = "10.3109/02656736.2013.793406",
language = "English (US)",
volume = "29",
pages = "380--389",
journal = "International Journal of Hyperthermia",
issn = "0265-6736",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - The 'peptidome' of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity

AU - Graner, Michael W.

AU - Romanoski, Angela

AU - Katsanis, Emmanuel

PY - 2013/8

Y1 - 2013/8

N2 - Tumour-derived chaperone-rich cell lysate (CRCL) when isolated from tumour tissue or when embedded with peptide antigens is a potent anti-cancer vaccine consisting of numerous chaperone/heat shock proteins, including the highly immunogenic Hsp70, Hsp90, glucose regulated protein 94, and calreticulin. We have previously documented that CRCL provides both a source of tumour antigens and danger signals triggering antigen presenting cell activation. In this report we describe the 'peptidome' of potential antigens extracted from CRCL prepared from a murine tumour. Using mass spectrometry techniques we identify almost 60 different proteins of origin for the CRCL peptides; we determine that the parental proteins come from essentially all parts of the cell, and are involved in a broad range of functions. Further in silico analysis demonstrates that the parental proteins are components of major signalling networks of vital importance for cancer cell survival, proliferation, and migration. In many instances the peptides identified possess amino acid sequences that would allow their putative binding and display by murine major histocompatibility complex class I and II molecules, and there are also predicted binding motifs for Hsp70-type chaperones. By mixing fractionated pools of peptides with antigen-free (normal liver) CRCL, we were able to reconstitute effective anti-tumour activity of the vaccine, showing that the peptides are indeed the major purveyors of CRCL vaccines' efficacy.

AB - Tumour-derived chaperone-rich cell lysate (CRCL) when isolated from tumour tissue or when embedded with peptide antigens is a potent anti-cancer vaccine consisting of numerous chaperone/heat shock proteins, including the highly immunogenic Hsp70, Hsp90, glucose regulated protein 94, and calreticulin. We have previously documented that CRCL provides both a source of tumour antigens and danger signals triggering antigen presenting cell activation. In this report we describe the 'peptidome' of potential antigens extracted from CRCL prepared from a murine tumour. Using mass spectrometry techniques we identify almost 60 different proteins of origin for the CRCL peptides; we determine that the parental proteins come from essentially all parts of the cell, and are involved in a broad range of functions. Further in silico analysis demonstrates that the parental proteins are components of major signalling networks of vital importance for cancer cell survival, proliferation, and migration. In many instances the peptides identified possess amino acid sequences that would allow their putative binding and display by murine major histocompatibility complex class I and II molecules, and there are also predicted binding motifs for Hsp70-type chaperones. By mixing fractionated pools of peptides with antigen-free (normal liver) CRCL, we were able to reconstitute effective anti-tumour activity of the vaccine, showing that the peptides are indeed the major purveyors of CRCL vaccines' efficacy.

KW - Cancer vaccine

KW - Heat shock proteins

KW - Peptide antigens

KW - Tumour immunity

UR - http://www.scopus.com/inward/record.url?scp=84881177227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881177227&partnerID=8YFLogxK

U2 - 10.3109/02656736.2013.793406

DO - 10.3109/02656736.2013.793406

M3 - Article

C2 - 23725202

AN - SCOPUS:84881177227

VL - 29

SP - 380

EP - 389

JO - International Journal of Hyperthermia

JF - International Journal of Hyperthermia

SN - 0265-6736

IS - 5

ER -